Skip to main content

Diebold Nixdorf Reshapes Leadership to Accelerate Global Growth and Operational Excellence

Submitted by J. Mikhail on
Image
Diebold Nixdorf Reshapes Leadership to Accelerate Global Growth and Operational Excellence

SHERIDAN, WYOMING – October 15, 2025 – Diebold Nixdorf (NYSE: DBD), a global technology leader in connected commerce for banking and retail, has announced two key executive appointments aimed at unifying commercial operations and strengthening administrative efficiency worldwide. Joe Myers will become Chief Revenue Officer (CRO) starting January 1, 2026, while Elizabeth (Lisa) Radigan will assume the newly created role of Chief Administrative Officer (CAO) effective December 1, 2025.

SIPA XTRA 8 Redefines Refillable PET Bottles with Smart, Sustainable Blowmolding Technology

Submitted by J. Mikhail on
Image
SIPA XTRA 8 Redefines Refillable PET Bottles with Smart, Sustainable Blowmolding Technology

SHERIDAN, WYOMING – October 15, 2025 – SIPA is charting the future of refillable PET packaging with the debut of its XTRA 8 rotary blowmolder at Drinktec 2025, introducing an advanced, digitally intelligent platform that blends speed, sustainability, and precision engineering. Designed for the next generation of returnable bottle systems, the XTRA 8 positions SIPA as a frontrunner in the race toward smarter and greener beverage production.

SIPA’s XLABL RF Sets a New Standard for High-Speed Roll-Fed Labelling in PET Bottling

Submitted by J. Mikhail on
Image
SIPA’s XLABL RF Sets a New Standard for High-Speed Roll-Fed Labelling in PET Bottling

SHERIDAN, WYOMING – October 15, 2025 – SIPA, a global leader in PET packaging and bottling technology, has introduced its new XLABL RF rotary roll-fed labeller — a breakthrough that completes the company’s fully integrated Sincro Tribloc System. This new machine enables a unified production flow from blowing and filling to labelling, achieving record-setting speeds of up to 90,000 bottles per hour.

SIPA’s XFORM PRO and XBrain: Redefining High-Cavitation PET Preform Production with Intelligent Efficiency

Submitted by J. Mikhail on
Image
SIPA’s XFORM PRO and XBrain: Redefining High-Cavitation PET Preform Production with Intelligent Efficiency

SHERIDAN, WYOMING – October 15, 2025 – SIPA has unveiled the XFORM PRO, a next-generation PET preform system that merges mechanical innovation with digital intelligence. Building on the success of the XFORM Gen 4, the new platform delivers faster cycles, lower energy use, and seamless integration with the company’s new XBrain telemetric mold management system—marking a major leap forward in high-cavitation PET preform manufacturing.

SIPA Expands Preform Manufacturing Range with Compact and Scalable XFORM 160 System

Submitted by J. Mikhail on
Image
SIPA Expands Preform Manufacturing Range with Compact and Scalable XFORM 160 System

SHERIDAN, WYOMING – October 15, 2025 – Italian packaging technology leader SIPA has introduced the new XFORM 160, a smart and scalable preform production system that targets low- to mid-volume bottlers and converters seeking high performance without high complexity. Positioned as the entry-level model in SIPA’s now fully integrated XFORM lineup—which includes the 160, 250, 350, and 500 systems—the machine marks a strategic move to make advanced preform manufacturing accessible to a broader range of producers.

SIPA’s Sincro Tribloc Redefines PET Bottling with Fully Integrated High-Speed Line

Submitted by J. Mikhail on
Image
SIPA’s Sincro Tribloc Redefines PET Bottling with Fully Integrated High-Speed Line

SHERIDAN, WYOMING – October 15, 2025 – SIPA has introduced the Sincro Tribloc, a fully integrated PET bottling solution that combines blowing, labelling, and filling in one compact unit. Designed for ultra-high-speed operations of up to 90,000 bottles per hour, the system redefines efficiency and sustainability standards for beverage manufacturers seeking leaner production and reduced total cost of ownership.

SIPA Launches ECS SP130 to Redefine ISBM Packaging Efficiency and Flexibility

Submitted by J. Mikhail on
Image
SIPA Launches ECS SP130 to Redefine ISBM Packaging Efficiency and Flexibility

SHERIDAN, WYOMING – October 15, 2025 – Italian engineering firm SIPA has unveiled the ECS SP130, a next-generation Injection-Stretch-Blow Molding (ISBM) system that marks a major leap forward in packaging production. Designed entirely in Italy, the new machine is built to set a new global benchmark for productivity, quality, and operational versatility in the manufacturing of plastic containers.

Lilly’s Oral GLP-1 Candidate Outperforms AstraZeneca’s Farxiga in Late-Stage Diabetes Trials

Submitted by J. Mikhail on
Image
Lilly’s Oral GLP-1 Candidate Outperforms AstraZeneca’s Farxiga in Late-Stage Diabetes Trials

SHERIDAN, WYOMING – October 15, 2025 – Eli Lilly’s investigational oral GLP-1 receptor agonist, orforglipron, has achieved another major milestone in its late-stage clinical program. Following its earlier success against Novo Nordisk’s semaglutide, the once-daily oral therapy has now demonstrated superiority over AstraZeneca’s blockbuster Farxiga (dapagliflozin) in two Phase III studies targeting patients with inadequately controlled type 2 diabetes.

Sarepta’s SRP-9003 Gene Therapy Shows Clinical Promise but Faces FDA Uncertainty

Submitted by J. Mikhail on
Image
Sarepta’s SRP-9003 Gene Therapy Shows Clinical Promise but Faces FDA Uncertainty

SHERIDAN, WYOMING – October 15, 2025 – Sarepta Therapeutics is pressing forward with its limb-girdle muscular dystrophy (LGMD) gene therapy, SRP-9003, despite a strategic pivot earlier this year toward small interfering RNA (siRNA) therapies and ongoing regulatory challenges. New late-stage data presented at the World Muscle Society Congress in Vienna suggest the therapy could still hold clinical and commercial potential—if Sarepta can navigate FDA scrutiny and rebuild trust in its gene therapy platform.

Pelage Pharmaceuticals Secures $120 Million to Advance Stem Cell-Based Hair Regrowth Therapy into Phase III

Submitted by J. Mikhail on
Image
Pelage Pharmaceuticals Secures $120 Million to Advance Stem Cell-Based Hair Regrowth Therapy into Phase III

SHERIDAN, WYOMING – October 15, 2025 – Pelage Pharmaceuticals has raised $120 million in Series B financing to advance its novel stem cell–activating therapy for hair loss into Phase III clinical trials. The funding positions the California-based biotech to accelerate clinical development of PP405, a first-in-class topical molecule designed to rejuvenate dormant hair follicle stem cells and restore natural hair growth.